New York University has teamed up with corporate-backed biopharmaceutical incubator Futurx to spawn neurodegenerative disease drug developer Glixogen Therapeutics.

Futurx, a biopharmaceutical incubator supported by pharmaceutical developers Johnson & Johnson (J&J) and Takeda Pharmaceutical, formally unveiled Israel-based Glixogen Therapeutics yesterday to design drugs based on New York University (NYU) research.
Glixogen Therapeutics will specialise in treatments for neurodegenerative disorders such as multiple sclerosis, focusing on the mitigation of a process called demyelination which destroys protective sheets insulating the nervous system known as myelin.
The company’s primary program will inhibit a pathway protein called Gli1 to help populate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?